RELATED PARTY TRANSACTIONS

6 Months Ended

Sep. 30, 2023

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

NOTE 2 – RELATED PARTY TRANSACTIONS

DDL has a service agreement with Nemaura Pharma Limited (“Pharma”), an entity controlled by the Company’s President and Chief Executive officer, to provide development, manufacture, and regulatory approval process under Pharma’s ISO13485 accreditation. Pharma invoices DDL for these services on a cost-plus basis.

The table below provides a summary of activity between the Company and Pharma for the six months ended September 30, 2023 and 2022.

	Six Months Ended September 30, 2023 (unaudited)			Six Months Ended September 30, 2022 (unaudited)
Due to (from) related parties at beginning of period	$	920,782		$	(101,297	)
Amounts invoiced by Pharma to DDL, NM and TCL, primarily relating to research and development expenses		2,907,192			1,833,706
Amounts invoiced by DDL to Pharma		—			(2,437	)
Amounts paid by DDL to Pharma		(3,735,011	)		(1,695,999	)
Foreign exchange differences		2,834			88,408
Due to (from) related parties at end of period	$	95,797		$	122,381